The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
“Given his general management and commercial experience, we are confident that Per is the right person to lead us through the next phases of development,” says Chairman of the Board Göran Lerenius, who continues:
“Through this appointment PharmNovo is strengthening the organisation on both the scientific and commercial sides, whilst maintaining full focus on the continued pre-clinical development.
The company’s founder and former CEO, Bengt von Mentzer, remains critical to PharmNovo´s business activities and will now focus even more of his time and efforts on the PN6047 development and the upcoming Regulatory Toxicology programme.
At the Extraordinary General Meeting held in May at Medicon Village, Lund, Sweden, Chairman of the Board Göran Lerenius thanked Bengt for founding the company and for leading it successfully over many years.
Per von Mentzer appointed as new CEO
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
Read more →JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Read more →Moving into The Spark
In September PharmNovo AB officially moved to Medicon Village in Lund and the newly opened building ”The Spark”. Being located at Medicon Village offers great opportunities for networking and finding new collaboration and service partners. Being one of the largest life science hubs in the Nordics, Medicon is also a fantastic platform for marketing our company and attracting future investors and partners.
Read more →Christmas BPS
A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17–20th December). The communication was given by Dr Alex Conibear who is working in Prof Eamonn Kelly’s research group at the University of Bristol funded by a Medical Research Council project grant to PharmNovo and Prof Kelly for the study of biased signalling via delta opioid receptors. The potential clinical use of PN6047 for the treatment of chronic pain and, in particular, mechanical allodynia, was explained and a detailed account of its biased signalling profile was given.
Read more →
